The company presented the data at ESC 2023 & published in The Lancet from an investigator-sponsored EU (MONITOR-HF) trial evaluating the CardioMEMS HF system in 348 patients at 25 centers in the Netherlands
The trial met its 1EPs & showed a clinical improvement in QoL as quantified by a 7-point mean increase in KCCQ score vs the control group who did not receive the pressure sensor & whose scores decreased as early as 3mos. after use with a remote monitoring sensor
44% reduction in HF-related hospitalizations for those who used guideline-directed medical therapy & showed health benefits. CardioMEMS, a paperclip-sized sensor that can remotely flag to a patient’s clinical team the early warning signs of worsening HF
Ref: PR Newswire | Image: Abbott
Related News:- Abbott’s CardioMEMS HF System Receives the US FDA’s Approval for the Treatment of Heart Failure
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
